Evidence map›Paper›PMID 26415052›Full record

ArticleThe Journal of pathology2016

In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.

Yusuke Yamamoto, Gang Ning, Brooke E Howitt, Karishma Mehra, Lingyan Wu, Xia Wang, Yue Hong, Florian Kern, Tay Seok Wei, Ting Zhang and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 76 citations in OpenAlex.

  1. Tubal epithelial alterations: evolving concepts.Journal of gynecologic oncology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Yusuke Yamamoto *The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Gang Ning *The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Brooke E HowittDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Karishma MehraDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Lingyan WuGenome Institute of Singapore, A-STAR, Singapore.
Xia WangThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Yue HongThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Florian KernGenome Institute of Singapore, A-STAR, Singapore.
Tay Seok WeiGenome Institute of Singapore, A-STAR, Singapore.
Ting ZhangGenome Institute of Singapore, A-STAR, Singapore.
Niranjan NagarajanGenome Institute of Singapore, A-STAR, Singapore.
Debargha BasuliDepartments of Molecular, Microbial and Structural Biology, University of Connecticut Health Center, Farmington, CT, USA.
Suzy TortiDepartments of Molecular, Microbial and Structural Biology, University of Connecticut Health Center, Farmington, CT, USA.
Molly BrewerDepartment of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, CT, USA.
Mahesh ChoolaniDivision of Obstetrics and Gynecology, National University of Singapore, Singapore.
Frank McKeonThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Christopher P CrumDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Wa XianThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Agency for Science, Technology and Research · SGJackson Laboratory · USUConn Health · USBrigham and Women's Hospital · USGenome Institute of Singapore · SGMirna Therapeutics (United States) · USNational University of Singapore · SG

Funding

Iron, Ferroptosis and Ovarian CancerR01CA188025 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI TORTI, SUZY V · 2014 to 2024
$3.9M
NCI NIH HHS R01 CA188025
6 · The paper itself

Abstract

High-grade serous cancer (HGSC) progresses to advanced stages without symptoms and the 5-year survival rate is a dismal 30%. Recent studies of ovaries and Fallopian tubes in patients with BRCA1 or BRCA2 mutations have documented a pre-metastatic intramucosal neoplasm that is found almost exclusively in the Fallopian tube, termed 'serous tubal intraepithelial carcinoma' or STIC. Moreover, other proliferations, termed p53 signatures, secretory cell outgrowths (SCOUTs), and lower-grade serous tubal intraepithelial neoplasms (STINs) fall short of STIC but share similar alterations in expression, in keeping with an underpinning of genomic disturbances involved in, or occurring in parallel with, serous carcinogenesis. To gain insight into the cellular origins of this unique tubal pathway to high-grade serous cancer, we cloned and both immortalized and transformed Fallopian tube stem cells (FTSCs). We demonstrated that pedigrees of FTSCs were capable of multipotent differentiation and that the tumours derived from transformed FTSCs shared the histological and molecular features of HGSC. We also demonstrated that altered expression of some biomarkers seen in transformed FTSCs and HGSCs (stathmin, EZH2, CXCR4, CXCL12, and FOXM1) could be seen as well in immortalized cells and their in vivo counterparts SCOUTs and STINs. Thus, a whole-genome transcriptome analysis comparing FTSCs, immortalized FTSCs, and transformed FTSCs showed a clear molecular progression sequence that is recapitulated by the spectrum of accumulated perturbations characterizing the range of proliferations seen in vivo. Biomarkers unique to STIC relative to normal tubal epithelium provide a basis for novel detection approaches to early HGSC, but must be viewed critically given their potential expression in lesser proliferations. Perturbations shared by both immortalized and transformed FTSCs may provide unique early targets for prevention strategies. Central to these efforts has been the ability to clone and perpetuate multipotent FTSCs.

Indexed as

Biomarkers, TumorCarcinoma in SituCystadenocarcinoma, SerousFallopian Tube NeoplasmsFemaleHumansNeoplasms, Cystic, Mucinous, and SerousNeoplastic Stem CellsOvarian NeoplasmsBiomarkers, Tumorcell cultureFallopian tubesneoplasiaovary

Identifiers

PMID26415052
PMCPMC4895925
OpenAlexW2117938759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.